EADV Berlin 2023 Discovering new Horizons in HS EADV Berlin 2023 Discovering new Horizons in Hidradenitis Suppurativa BE2312051321 Start 1. The multifaceted nature of HS and the need for effective treatments 2. HS core domain set; outcomes that matter most to patients 3. The challenge to develop successful treatments in HS 4. Secukinumab demonstrates sustained improvement in moderate to severe HS 5. Tackling the burden of pain and flares in HS 6. Beyond the lesions; improving quality of life for HS patients 7. The window of opportunity in HS 8. New German guidelines for the treatment of HS 9. Pathogenesis-based targets in HS BE2312205567Dermatology Share Twitter Linkedin Facebook Pinterest Google plus Print
